Alexander Bershadskiy, MD

home / authors / alexander-bershadskiy-md

Articles

Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

Muhammad Rafay Khan Niazi, MD;Alexander Bershadskiy, MD

April 26th 2022

Muhammad Rafay Khan Niazi, MD, and Alexander Bershadskiy, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the use of PARP inhibitors as maintenance therapy for certain patients with metastatic castration-resistant prostate cancer.

The Prognostic Significance of Peripheral Blood Biomarkers in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab: A Clinical Study

Kira MacDougall, MD;Muhammad Rafay Khan Niazi, MD;Jeff Hosry MD;Sylvester Homsy, MD;Alexander Bershadskiy, MD

March 16th 2022

Kira MacDougall, MD, and co-investigators, research the importance of peripheral biomarkers in patients with advanced non–small cell lung cancer who are treated with pembrolizumab.

Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials

Muhammad Rafay Khan Niazi, MD;Abdullah Jahangir, MD;Syeda Sahra, MD;Saud Bin Abdul Sattar, MD;Divya Asti, MD;Alexander Bershadskiy, MD

November 18th 2021

The aim of this meta-analysis is to analyze the efficacy of these drugs in the treatment of mCRPC in terms of progression-free survival (PFS) and overall survival (OS), using the results of completed trials.